Carbapenem-resistant Enterobacteriaceae infections: Results from a retrospective series and implications for the design of prospective clinical trials

Open Forum Infectious Diseases

Volumn 4, Issue 2, 2017, Pages

  Alexander, Elizabeth L ^a   Loutit, Jeffery ^b   Tumbarello, Mario ^c   Wunderink, Richard ^d   Felton, Tim ^e   Daikos, George ^f   Fusaro, Karen ^a   White, Dan ^a   Zhang, Shu ^a   Dudley, Michael N ^b  

^a MEDICINES COMPANY   (United States)

^b The Medicines Company   (United States)

^c FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^d NORTHWESTERN UNIVERSITY   (United States)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

^f UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Antibiotics; Carbapenem resistant Enterobacteriaceae; Clinical trials; Mortality

Indexed keywords

AMIKACIN; CARBAPENEM; GENTAMICIN; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN; SULTAMICILLIN; TIGECYCLINE; TOBRAMYCIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; BACTEREMIA; BACTERIAL PNEUMONIA; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; CHRONIC KIDNEY FAILURE; ENTEROBACTERIACEAE INFECTION; FEMALE; HOSPITAL DISCHARGE; HOSPITAL INFECTION; HUMAN; LENGTH OF STAY; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PYELONEPHRITIS; RETROSPECTIVE STUDY; SEPSIS; SEPTIC SHOCK; TACHYCARDIA; URINARY TRACT INFECTION; VENTILATOR ASSOCIATED BACTERIAL PNEUMONIA;

EID: 85031915279     PISSN: None     EISSN: 23288957     Source Type: Journal    
DOI: 10.1093/ofid/ofx063     Document Type: Article

References (40)

1. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:1-12
2. US Department of Health and Human Services, Center for Disease Control and Prevention. Antibiotic Resistance Threats in the United States. Atlanta, GA: 2013; 1-12. Available at: https://www.cdc.gov/drugresistance/threat-report-2013/pdf/ ar-threats-2013-508.pdf. Accessed 12 March 2016
3. Nambiar S, Laessig K, Toerner J, et al. Antibacterial drug development: challenges, recent developments, and future considerations. Clin Pharmacol Ther 2014; 96:147-9
4. Boucher HW. Challenges in anti-infective development in the era of bad bugs, no drugs: a regulatory perspective using the example of bloodstream infection as an indication. Clin Infect Dis 2010; 50(Suppl 1):S4-9
5. US Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Guidance for Industry. Antibacterial Therapies for Patients with Unmet Medical Need for the Treatment of Serious Bacterial Diseases Draft Guidance. Available at: www.fda.gov/downloads/ drugs/guidancecomplianceregulatoryinformation/guidances/ucm359184. pdf. Accessed 6 February 2016
6. ClinicalTrials.gov. Search for Studies. Available at: http://www.clinicaltrials.gov. Accessed 1 December 2015
7. ClinicalTrials.gov. Efficacy, Safety, Tolerability of Meropenem-Vaborbactam Compared to Best Available Therapy in Serious Infections Due to Carbapenem Resistant Enterobacteriaceae, in Adults. Available at: https://clinicaltrials.gov/ show/NCT02168946. Accessed 11 March 2016
8. Rex JH, Eisenstein BI, Alder J, et al. A comprehensive regulatory framework to address the unmet need for new antibacterial treatments. Lancet Infect Dis 2013; 13:269-75
9. Hecker SJ, Reddy KR, Totrov M, et al. Discovery of a cyclic boronic acid β-lactamase inhibitor (RPX7009) with utility vs class a serine carbapenemases. J Med Chem 2015; 58:3682-92
10. Falagas ME, Lourida P, Poulikakos P, et al. Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence. Antimicrob Agents Chemother 2014; 58:654-63
11. Tumbarello M, Trecarichi EM, Tumietto F, et al. Predictive models for identification of hospitalized patients harboring KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2014; 58:3514-20
12. Munoz-Price LS, Poirel L, Bonomo RA, et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis 2013; 13:785-96
13. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/ Society of Critical Care Medicine. Chest 1992; 101:1644-55
14. CLSI. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fourth Informational Supplement M100-S24. Wayne, PA; Clinical and Laboratory Standards Institute; 2014
15. Patel G, Huprikar S, Factor SH, et al. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008; 29:1099-106
16. Liu SW, Chang HJ, Chia JH, et al. Outcomes and characteristics of ertapenem-nonsusceptible Klebsiella pneumoniae bacteremia at a university hospital in Northern Taiwan: a matched case-control study. J Microbiol Immunol Infect 2012; 45:113-9
17. US Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Guidance for Industry. Complicated Urinary Tract Infections: Developing Drugs for Treatment. Available at: http://www.fda.gov/downloads/drugs/./guidances/ucm070981.pdf. Accessed 30 July 2016
18. US Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Guidance for Industry. Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia: Developing Drugs for Treatment. Available at: http://www.fda. gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ ucm234907.pdf. Accessed 30 July 2016
19. US Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Guidance for Industry. Catheter-Related Bloodstream Infections-Developing Antimicrobial Drugs for Treatment. Available at: http://www.fda.gov/ohrms/dockets/ac/99/backgrd/ 3558b1a.pdf. Accessed 30 July 2016
20. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol 1994; 47:1245-51
21. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13:818-29
22. Carmeli Y, Armstrong J, Laud PJ, et al. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomized, pathogen-directed, phase 3 study. Lancet Infect Dis 2016; 16:661-73
23. Mazuski JE, Gasink LB, Armstrong J, et al. Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program. Clin Infect Dis 2016; 62:1380-9
24. Wagenlehner FM, Umeh O, Steenbergen J, et al. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECTcUTI). Lancet 2015; 385:1949-56
25. ClinicalTrials.gov. Study of the Safety, Tolerability and Efficacy of MK-7655+Imipenem+Cilastin versus Imipenem+Cilastin Alone for the Treatment of Complicated Urinary Tract Infection (MK-7655-003). Accessed 11 March 2016
26. ClinicalTrials.gov. A Study of Plazomicin Compared with Meropenem for the Treatment of Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis. Available at: https://clinicaltrials.gov/ct2/show/ NCT02486627?term=Achaogen&rank=1. Accessed 18 May 2016
27. ClinicalTrials.gov. Efficacy and Safety of Imipenem+Cilastin/Relebactam (MK-7655A) versus Colistimethate Sodium + Imipenem+Cilastin In Imipenem-Resistant Bacterial Infection (MK-7655A-013) (RESTORE-IMI 1). Available at: https://clinicaltrials.gov/ct2/show/ NCT02452047?term=imipenem+RESTORE&rank=1. Accessed 16 May 2016
28. ClinicalTrials.gov. A Study of Plazomicin Compared with Colistin in Patients with Infection due to Carbapenem-Resistant Enterobacteriaceae (CRE) (CARE). Available at: https://clinicaltrials.gov/ct2/show/ NCT01970371?term=CARE+achaogen&rank=1. Accessed 16 May 2016
29. Daikos GL, Tsaousi S, Tzouvelekis LS, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother 2014; 58:2322-8
30. Tumbarello M, Viale P, Viscoli C, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis 2012; 55:943-50
31. Viale P, Giannella M, Lewis R, et al. Predictors of mortality in multidrug-resistant Klebsiella pneumoniae bloodstream infections. Expert Rev Anti Infect Ther 2013; 11:1053-63
32. Palacios-Baena ZR, Oteo J, Conejo C, et al. Comprehensive clinical and epidemiological assessment of colonisation and infection due to carbapenemase-producing Enterobacteriaceae in Spain. J Infect 2016; 72:152-60
33. Wagenlehner FM, Sobel JD, Newell P, et al. Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program. Clin Infect Dis 2016; 63:754-62
34. Daikos GL, Petrikkos P, Psichogiou M, et al. Prospective observational study of the impact of VIM-1 metallo-beta-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections. Antimicrob Agents Chemother 2009; 53:1868-73
35. Qureshi ZA, Paterson DL, Potoski BA, et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother 2012; 56:2108-13
36. Tumbarello M, Trecarichi EM, De Rosa FG, et al. Infections caused by KPCproducing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. J Antimicrob Chemother 2015; 70:2133-43
37. Giacobbe DR, Del Bono V, Trecarichi EM, et al. Risk factors for bloodstream infections due to colistin-resistant KPC-producing Klebsiella pneumoniae: Results from a multicenter case-control-control study. Clin Microbiol Infect 2015; 21:1106.e1-8
38. Monaco M, Giani T, Raffone M, et al. Colistin resistance superimposed to endemic carbapenem-resistant Klebsiella pneumoniae: a rapidly evolving problem in Italy, November 2013 to April 2014. Euro Surveillance 2014; 19:20903
39. Spellberg B, Srinivasan A, Chambers HF. New societal approaches to empowering antibiotic stewardship. JAMA 2016; 315:1229-30
40. McKinnell JA, Arias CA. Editorial Commentary: Linezolid vs daptomycin for vancomycin-resistant enterococci: the evidence gap between trials and clinical experience. Clin Infect Dis 2015; 61:879-82